Fondaparinux suppresses VEGF release from human platelets after exposure to MCF-7 cells or ADP. (A) VEGF concentration in the releasate generated from platelets resting or exposed to MCF-7 cells after exposure to fondaparinux. (B) VEGF concentration in the releasate generated from platelets activated with 25 μM ADP after exposure to fondaparinux. (C) Immunofluorescence of platelets resting, exposed to MCF-7 cells, or activated with 25 μM ADP after exposure to fondaparinux and labeled with endostatin (red) or VEGF (green). *P < .05. Bars represent 300 μM.